Complete Remission of Unresectable Esophageal Cancer Achieved with Concurrent Chemoradiotherapy: A Case Report

  • Jung Min Lee (Division of Gastroenterology and Hepatology, Department of Internal Medicine, Korea University College of Medicine) ;
  • Bora Keum (Division of Gastroenterology and Hepatology, Department of Internal Medicine, Korea University College of Medicine) ;
  • Sang Yup Lee (Division of Gastroenterology and Hepatology, Department of Internal Medicine, Korea University College of Medicine) ;
  • In Kyung Yoo (Division of Gastroenterology and Hepatology, Department of Internal Medicine, Korea University College of Medicine) ;
  • Seung Han Kim (Division of Gastroenterology and Hepatology, Department of Internal Medicine, Korea University College of Medicine) ;
  • Hyuk Soon Choi (Division of Gastroenterology and Hepatology, Department of Internal Medicine, Korea University College of Medicine) ;
  • Eun Sun Kim (Division of Gastroenterology and Hepatology, Department of Internal Medicine, Korea University College of Medicine) ;
  • Hoon Jai Chun (Division of Gastroenterology and Hepatology, Department of Internal Medicine, Korea University College of Medicine)
  • Received : 2016.06.14
  • Accepted : 2017.06.22
  • Published : 2017.06.30

Abstract

A 41-year old woman with dysphagia visited, which was aggravated after eating. On physical examination, there was a palpable mass on the left supraclavicular area. Endoscopic examination revealed a mass on the distal esophagus with irregular mucosa, erythema and a whitish plaque with luminal narrowing. The patient was diagnosed with unresectable esophageal cancer (squamous cell carcinoma, T3N2M1, Stage IV). The patient received CCRT (total 63 Gy) with cisplatin and 5-fluorouracil (5-FU). After CCRT, the patient took an additionally 2 cycles of chemotherapy for consolidation (cisplatin and 5-FU every 4 weeks). After additional chemotherapy, endoscopic examination showed no residual tumor, a chest CT scan revealed that the mass in the distal esophagus had decreased and there was no enlargement of the lymph nodes around the left supraclavicular area. The patient has been in complete remission for 5 years.

Keywords

References

  1. van Hagen P, Hulshof MC, van Lanschot JJ, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 2012;366:2074-2084.
  2. Ohtsu A, Boku N, Muro K, et al. Definitive chemoradiotherapy for T4 and/or M1 lymph node squamous cell carcinoma of the esophagus. J Clin Oncol 1999;17:2915-2921.
  3. Jaffer A. Ajani TADA, Khaldoun Almhanna National Comprehensive Cancer Network. Volume Version 1.2016.
  4. Coia LR, Soffen EM, Schultheiss TE, et al. Swallowing function in patients with esophageal cancer treated with concurrent radiation and chemotherapy. Cancer 1993;71:281-286.
  5. Minsky BD, Pajak TF, Ginsberg RJ, et al. INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol 2002;20:1167-1174.
  6. Stahl M, Stuschke M, Lehmann N, et al. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol 2005;23:2310-2317.
  7. Bleiberg H1 CT, Paillot B, Lacave AJ, et al. Randomized phase II study of cisplatin and 5-fluorouracil (5-FU) versus cisplatin alone in advanced squamous cell oesophageal cancer. Eur J Cancer 1997;33:1216-1220.
  8. Conroy T, Galais MP, Raoul JL, et al. Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial. Lancet Oncol 2014;15:305-314.
  9. Feliu J, Baron MG, Giron CG, et al. Phase II study of cisplatin, 5-fluorouracil, and leucovorin in inoperable squamous cell carcinoma of the esophagus. American Journal of Clinical Oncology-Cancer Clinical Trials 1996;19:577-580.